EHR

athenahealth, Availity, Harmony Park Family Medicine, and Humana Honored with a 2024 KLAS Points of Light Award for Modernizing Prior Authorization Process

Seamless Data Exchange Improves Patient Access to Care, Reduces Administrative Burden Across the Healthcare EcosystemBOSTON--(BUSINESS WIRE)--athenahealth, a leading provider of...

The American Journal of Managed Care Study Confirms Real Time Medical Systems’ Interventional Analytics Platform Significantly Reduces Readmissions Among Skilled Nursing Facilities

Study establishes pattern of outperformance among Penn Medicine’s Lancaster General Hospital associated SNFs utilizing company’s analytics platform, pointing to potential...

AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim

AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June...

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer progression-free survival versus osimertinib in the first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer

Investigational chemotherapy-free regimen of amivantamab plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk...

Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML

Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR...

error: Content is protected !!